<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Comparator products in Bioequivalence/Therapeutic Equivalence studies from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">This guidance provides further information on comparator products used in studies supporting abridged marketing authorisation applications</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">For current information, read: </p>
            <ul class="app-c-header-notice__list govuk-list">
                <li><a data-module="track-click" data-track-category="no_deal_notice" data-track-action="https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/vol2a_chap1_en.pdf" data-track-label="Volume 2a: Procedures for marketing authorisation" class="app-c-header-notice__link" href="https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/vol2a_chap1_en.pdf">Volume 2a: Procedures for marketing authorisation</a></li>
                <li><a data-module="track-click" data-track-category="no_deal_notice" data-track-action="https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-efficacy-safety-clinical-pharmacology-pharmacokinetics" data-track-label="Clinical efficacy and safety: clinical pharmacology and pharmacokinetics" class="app-c-header-notice__link" href="https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-efficacy-safety-clinical-pharmacology-pharmacokinetics">Clinical efficacy and safety: clinical pharmacology and pharmacokinetics</a></li>
            </ul>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#introduction" data-track-options="{"dimension29":"Introduction"}" href="#introduction">Introduction</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#scope" data-track-options="{"dimension29":"Scope"}" href="#scope">Scope</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#general-principles" data-track-options="{"dimension29":"General principles"}" href="#general-principles">General principles</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 4" data-track-label="#contact" data-track-options="{"dimension29":"Contact"}" href="#contact">Contact</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<p>The guidance is limited to applications intended for the Great Britain (England, Wales and Scotland) market only. Applications intended for Northern Ireland will be required to comply with <abbr title="European Union">EU</abbr> requirements for comparator products to be used in studies.</p>

<h2 id="introduction">Introduction</h2>

<h3 id="reference-medicinal-product">Reference Medicinal Product</h3>

<p>From 1 January 2021, <a href="https://www.gov.uk/guidance/reference-medicinal-products-rmps-from-1-january-2021" class="govuk-link">reference medicinal products (<abbr title="Reference medicinal products">RMP</abbr>)</a> for new generic medicines or other abridged marketing authorisation applications submitted from this date will be required to comply with the relevant legislation.</p>

<h3 id="comparator-products-used-in-bioequivalence-and-therapeutic-equivalence-studies">Comparator products used in bioequivalence and therapeutic equivalence studies</h3>

<p>Comparator products (<abbr title="Comparator products">CPs</abbr>) used in bioequivalence (<abbr title="Bioequivalence]">BE</abbr>), pharmacokinetic (<abbr title="Pharmacokinetic">PK</abbr>) and therapeutic equivalence (<abbr title="Therapeutic equivalence">TE</abbr>) studies supporting abridged applications should be representative of the <abbr title="Reference medicinal products">RMP</abbr> supporting the application.</p>

<p>Generally, the <abbr title="Comparator product">CP</abbr> should be sourced from Great Britain (England, Wales and Scotland). However, if the <abbr title="Comparator product">CP</abbr> is not sourced from the Great Britain hmarket, the applicant should provide evidence that it is representative of the <abbr title="Reference medicinal products">RMP</abbr>. This guidance document provides further information on the data required to demonstrate this.</p>

<h2 id="scope">Scope</h2>

<p>With the aim of facilitating the global development of medicinal products and to avoid unnecessary repetition of clinical <abbr title="Bioequivalence]">BE</abbr>/<abbr title="Therapeutic equivalence">TE</abbr> studies, it may be possible for an applicant to compare the proposed medicinal product with a non-Great Britain sourced <abbr title="Comparator product">CP</abbr>. The application for the new medicinal product would still be required to refer to an eligible <abbr title="Reference medicinal products">RMP</abbr>.</p>

<p>The purpose of demonstrating pharmaceutical equivalence and <abbr title="Bioequivalence]">BE</abbr> against the <abbr title="Comparator product">CP</abbr> is to provide evidence that the safety and efficacy profiles of the proposed product will be equivalent to that of the <abbr title="Reference medicinal products">RMP</abbr> and for which safety and efficacy has been demonstrated clinically.</p>

<p>In order to determine the acceptability of this evidence, the licensing authority must be satisfied that a non-Great Britain <abbr title="Comparator product">CP</abbr> is representative of the <abbr title="Reference medicinal products">RMP</abbr> and that any differences between these two products would not be therapeutically significant.</p>

<p>The following types of abridged applications are commonly supported by <abbr title="Bioequivalence]">BE</abbr> or <abbr title="Therapeutic equivalence">TE</abbr> studies and are within the scope of this guidance:</p>

<ul>
  <li>Applications relating to generic medicinal products (regulation 51 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>), equivalent to Article 10(1) of <abbr title="European Union">EU</abbr> Directive 2001/83</li>
  <li>Applications relating to certain medicinal products that do not qualify as generics etc (regulation 52 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>), equivalent to Article 10(3) of <abbr title="European Union">EU</abbr> Directive 2001/83</li>
</ul>

<p>This guidance applies to <abbr title="Bioequivalence]">BE</abbr>, <abbr title="Pharmacokinetic">PK</abbr> and <abbr title="Therapeutic equivalence">TE</abbr> studies provided in support of applications made under any of the above legal bases. In case of complex products, it is recommended that we are consulted for specific advice.</p>

<p>The principles may also be applicable to <abbr title="Bioequivalence]">BE</abbr>, <abbr title="Pharmacokinetic">PK</abbr> or <abbr title="Therapeutic equivalence">TE</abbr> studies conducted in support of other applications that are out of the scope of this guidance such as:</p>

<ul>
  <li>Applications relating to products in well-established medicinal use (regulation 54 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>), equivalent to Article 10a of <abbr title="European Union">EU</abbr> Directive 2001/83</li>
  <li>Applications relating to new combinations of active substances (regulation 55 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>), equivalent to Article 10b of <abbr title="European Union">EU</abbr> Directive 2001/83</li>
  <li>Variations requiring demonstration of <abbr title="Bioequivalence]">BE</abbr> to the <abbr title="Reference medicinal products">RMP</abbr> (e.g. for modified release solid oral dosage forms) (regulation 65C <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>)</li>
  <li>Extension applications (regulation 65C <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>)</li>
</ul>

<p>These principles may be applicable to certain non-clinical studies, for example those provided in support of “hybrid” applications (regulation 52 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>).</p>

<p>If the use of a non-Great Britain <abbr title="Comparator product">CP</abbr> is proposed for applications that are out of the scope of this guidance, early discussion with us is recommended to obtain the relevant regulatory and/or scientific advice.</p>

<p>Applications relating to similar biological medical products (regulation 53 <abbr title="Human Medicines (Amendment etc.) (EU Exit) Regulations 2019">HMRs</abbr>) are out of scope of this guidance.</p>

<p>This guidance should always be read in conjunction with relevant scientific guidelines and legislative provisions in force in the <abbr title="United Kingdom">UK</abbr>.</p>

<h2 id="general-principles">General principles</h2>

<p>The general principles that are applicable are described below. For more specific guidance, especially for more complex dosage forms, it is recommended that the applicant seeks scientific advice from us.</p>

<h3 id="responsibility">Responsibility</h3>

<p>It will be the applicant’s responsibility to demonstrate that any <abbr title="Comparator product">CP</abbr> authorised and sourced from outside the <abbr title="United Kingdom">UK</abbr> is representative of the <abbr title="Reference medicinal products">RMP</abbr>.</p>

<h3 id="source-country-of-non-great-britain-cp">Source country of non-Great Britain <abbr title="Comparator product">CP</abbr>
</h3>

<p>The non-Great Britain <abbr title="Comparator product">CP</abbr> should be authorised in and sourced from a country with similar scientific and regulatory standards as the <abbr title="United Kingdom">UK</abbr>. Examples would be:</p>

<ul>
  <li>
<abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr>
</li>
  <li>Switzerland</li>
  <li><abbr title="United States of America">USA</abbr></li>
  <li>Canada</li>
  <li>Australia</li>
  <li>Japan</li>
</ul>

<p>The non-Great Britain <abbr title="Comparator product">CP</abbr> would normally be expected to be:</p>

<ul>
  <li>part of the same global marketing authorisation (<abbr title="Global Marketing Authorisation">GMA</abbr>) as the <abbr title="Reference medicinal products">RMP</abbr>, or</li>
  <li>marketed in the country of origin through a licensing arrangement with the innovator company or corporate entity that currently markets the medicine in the Great Britain.</li>
</ul>

<p>The <abbr title="Global Marketing Authorisation">GMA</abbr> contains the initial authorisation and all variations and extensions. It includes any additional strengths, pharmaceutical form, administration routes or presentations authorised through separate procedures and under a different name, granted to the Marketing Authorisation Holder (<abbr title="Marketing Authorisation Holder">MAH</abbr>) of the initial authorisation.</p>

<h3 id="identicality-vs-representativeness">Identicality vs. representativeness</h3>

<p>The non-Great Britain <abbr title="Comparator product">CP</abbr> used is required to be representative of the <abbr title="Reference medicinal products">RMP</abbr>, but it is not required to be identical to it. This means that certain minor differences between both products may be accepted if justified, provided this is supported by bridging data (see below).</p>

<p>These differences could include but are not limited to:</p>

<ul>
  <li>Colour of tablet coatings (assuming no difference in functionality of coat) or capsule shells</li>
  <li>Scorelines, embossings and imprintings on solid dosage forms</li>
  <li>Flavours in liquid dosage forms</li>
  <li>Container closures</li>
</ul>

<h3 id="demonstration-of-identicality-of-the-non-great-britain-cp-to-the-rmp">Demonstration of identicality of the non-Great Britain <abbr title="Comparator product">CP</abbr> to the <abbr title="Reference medicinal products">RMP</abbr>
</h3>

<p>In cases where the applicant provides written confirmation from the <abbr title="Marketing Authorisation Holder">MAH</abbr> of the non-Great Britain <abbr title="Comparator product">CP</abbr> that the <abbr title="Comparator product">CP</abbr> is identical to the <abbr title="Reference medicinal products">RMP</abbr>, no further analytical data are required.</p>

<p>This written confirmation should confirm the following are identical in both products:</p>

<ul>
  <li>the route of synthesis of the drug substance(s)</li>
  <li>the drug substance specifications</li>
  <li>the finished product quantitative composition</li>
  <li>the manufacturing process including in-process controls</li>
  <li>the finished product specifications</li>
  <li>the stability data</li>
</ul>

<p>In cases where identicality can be confirmed, the use of a non-<abbr title="United Kingdom">UK</abbr> <abbr title="Comparator product">CP</abbr> is also acceptable for more complex formulations.</p>

<p>For the drug substance and finished products specifications, non-significant differences in specifications may be acceptable if fully justified.</p>

<h3 id="demonstration-of-representativeness-of-the-non-great-britain-cp-to-the-uk-rmp">Demonstration of representativeness of the non-Great Britain <abbr title="Comparator product">CP</abbr> to the <abbr title="United Kingdom">UK</abbr> <abbr title="Reference medicinal products">RMP</abbr>
</h3>

<p>If a <abbr title="Comparator product">CP</abbr> authorised and sourced from outside Great Britain is used, the applicant should provide adequate data or information to scientifically justify the relevance of these comparative data and establish an acceptable bridge to the <abbr title="Reference medicinal products">RMP</abbr>.</p>

<p>As a scientific matter, the type of bridging data needed should always include data from analytical studies that compare all 3 products:</p>

<ul>
  <li>Between the <abbr title="Reference medicinal products">RMP</abbr> and the non-Great Britain <abbr title="Comparator product">CP</abbr> to establish suitability of the latter as <abbr title="Comparator product">CP</abbr> in <abbr title="Bioequivalence]">BE</abbr>/<abbr title="Therapeutic equivalence">TE</abbr> studies</li>
  <li>Between the proposed medicinal product and the <abbr title="Reference medicinal products">RMP</abbr> to demonstrate similarity to allow bridging of the <abbr title="Reference medicinal products">RMP</abbr> data</li>
  <li>Between the proposed medicinal product and the non-Great Britain <abbr title="Comparator product">CP</abbr> to support the <abbr title="Bioequivalence]">BE</abbr>/<abbr title="Therapeutic equivalence">TE</abbr> studies</li>
</ul>

<p>Any observed differences in the data have to be duly justified with regard to their potential impact on safety and efficacy.</p>

<p>Only data requirements between the <abbr title="Reference medicinal products">RMP</abbr> and the non-<abbr title="United Kingdom">UK</abbr> <abbr title="Comparator product">CP</abbr> are discussed here; for other data requirements see current guidance.</p>

<p>The following information should be provided in Module 1.5.2 of the Common Technical Dossier structure for both the <abbr title="Reference medicinal products">RMP</abbr> and non-Great Britain <abbr title="Comparator product">CP</abbr>:</p>

<ul>
  <li>Name and address of the authorisation holder of the non-Great Britain <abbr title="Comparator product">CP</abbr> used, the product name, the country of authorisation, country of origin, and authorisation number</li>
  <li>Proof of purchase (batch number, date and place of purchase, expiry date)</li>
  <li>Samples in their original container closure systems should be available upon request</li>
  <li>Product information (Summary of Product Characteristics or equivalent)</li>
  <li>Certificates of analysis (tested according to the proposed specification for the proposed medicinal product)</li>
  <li>The excipients in the formulation of the <abbr title="Reference medicinal products">RMP</abbr>, when compared to the non-<abbr title="United Kingdom">UK</abbr> <abbr title="Comparator product">CP</abbr>, should be qualitatively the same. Any differences in excipients would need to be shown to have no effect on safety or efficacy</li>
  <li>If quantitative formulation information is available for these two products it should also show the non-Great Britain <abbr title="Comparator product">CP</abbr> to be representative of the <abbr title="Reference medicinal products">RMP</abbr>
</li>
</ul>

<p>The experimental comparison should include the physico-chemical properties and all critical product attributes of the medicinal product; these should include device attributes where appropriate. Where provided, dissolution data should cover the physiological pH range. Reference is also made to existing current guidance.</p>

<h3 id="number-of-batches-to-be-tested">Number of batches to be tested</h3>

<p>For the comparison between the <abbr title="Reference medicinal products">RMP</abbr> and the non-Great Britain <abbr title="Comparator product">CP</abbr>, data on at least 3 batches of each product would usually be expected.</p>

<p>In cases of products that exhibit a higher inherent batch-to-batch variability or that are complex, a larger number of batches might be required to establish representativeness.</p>

<h3 id="analytical-methods">Analytical methods</h3>

<p>The precision and accuracy of the analytical methods and the inter-batch variability are critical to deciding if the formulations of the <abbr title="Reference medicinal products">RMP</abbr> and non-Great Britain <abbr title="Comparator product">CP</abbr> are representative of each other. The analytical methods and analytical method validation reports used to generate the physicochemical data should be provided to satisfy this requirement.</p>

<h3 id="if-the-rmp-is-unavailable">If the <abbr title="Reference medicinal products">RMP</abbr> is unavailable</h3>

<p>Should the <abbr title="Reference medicinal products">RMP</abbr> not be marketed in Great Britain and not be available for the relevant comparison, the applicant should contact us for advice.</p>

<h3 id="acceptability-of-approach">Acceptability of approach</h3>

<p>The overall acceptability of such an approach and the type of bridging data needed will be a case-by-case/product-type decision and is recommended to be discussed upfront with us if one or more of the following applies to the product:</p>

<ul>
  <li>does not exhibit immediate release of the drug substance</li>
  <li>is not for oral administration</li>
  <li>is made by complex methods of manufacture</li>
  <li>exhibits a narrow therapeutic range or safety margin (for example, careful dosage titration or patient monitoring)</li>
  <li>has a steep dose-response relationship</li>
  <li>a risk of serious undesired effects</li>
  <li>complicated or variable pharmacokinetics (such as nonlinear pharmacokinetics, variable or incomplete absorption)</li>
  <li>an absorption window (i.e. site-specific absorption)</li>
  <li>substantial (e.g. greater than 40%) first-pass metabolism</li>
</ul>

<p>However, the final determination of the adequacy of the scientific justification and bridging will only be made during the assessment of the application. This will take the safety, efficacy and quality of the medicinal product into account.</p>

<p>If representativeness between the non-Great Britain <abbr title="Comparator product">CP</abbr> and the <abbr title="Reference medicinal products">RMP</abbr> cannot be demonstrated, <abbr title="Bioequivalence]">BE</abbr> and <abbr title="Therapeutic equivalence">TE</abbr> studies should be performed against the <abbr title="Reference medicinal products">RMP</abbr> in Great Britain</p>

<h2 id="contact">Contact</h2>

<p>For specific queries please contact <a href="mailto:RIS.NA@mhra.gov.uk" class="govuk-link">RIS.NA@mhra.gov.uk</a></p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-9524296d" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-9524296d" data-module="gem-toggle">

    <h3 id="related-nav-collections-9524296d" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-181259f6" data-module="gem-toggle">

    <h2 id="related-nav-topics-181259f6" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines" data-track-options="{"dimension28":"2","dimension29":"Manufacturing, wholesaling, importing and exporting medicines"}" href="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines">Manufacturing, wholesaling, importing and exporting medicines</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"2","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>